XML 62 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Debt (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
Summary of Borrowings of the Scilex Pharma Notes
Borrowings of the Scilex Notes consisted of the following (in thousands):

 
  
September 30,
2022
 
  
December 31,
2021
 
Principal
   $     
$
133,997  
Unamortized debt discount
            (30,597 )
Unamortized debt issuance costs
            (2,228
    
 
 
    
 
 
 
Carrying value
            101,172  
Current portion
            (29,135
    
 
 
    
 
 
 
Long term portion
            72,037  
    
 
 
    
 
 
 
Estimated fair value
   $      $ 115,400  
Borrowings of the Scilex Pharma Notes are as follows (in thousands):
 
 
  
December 31,
 
  
2021
 
  
2020
 
Principal
   $ 133,997      $ 151,872  
Unamortized debt discount
     (30,597      (51,022
Unamortized debt issuance costs
     (2,228      (3,711
    
 
 
    
 
 
 
Carrying value
     101,172        97,139  
Current portion
     (29,135      (4,881
    
 
 
    
 
 
 
Long term portion
     72,037        92,258  
    
 
 
    
 
 
 
Estimated fair value
   $ 115,400      $ 122,300  
Summary of Future Minimum Payments Under the Scilex Pharma Notes  
Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands):
 
Year Ending December 31,
  
2021
 
2022
   $ 29,135  
2023
     12,005  
2024
     13,637  
2025
     14,746  
2026
     64,474  
    
 
 
 
Total minimum future payments
   $ 133,997